Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials

Abstract The hunt for useful sepsis biomarkers is ongoing. Macrophage migration inhibitory factor (MIF) was implicated as a biomarker in sepsis, but its diagnostic and prognostic value has remained unclear in human studies. Here, we aimed at clarifying the value of MIF as a sepsis biomarker with the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Janos Toldi, David Nemeth, Peter Hegyi, Zsolt Molnar, Margit Solymar, Nelli Farkas, Hussain Alizadeh, Zoltan Rumbus, Eszter Pakai, Andras Garami
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2ced19890280486aa347af94b9db1a03
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2ced19890280486aa347af94b9db1a03
record_format	dspace
spelling	oai:doaj.org-article:2ced19890280486aa347af94b9db1a032021-12-02T18:03:21ZMacrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials10.1038/s41598-021-87613-02045-2322https://doaj.org/article/2ced19890280486aa347af94b9db1a032021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87613-0https://doaj.org/toc/2045-2322Abstract The hunt for useful sepsis biomarkers is ongoing. Macrophage migration inhibitory factor (MIF) was implicated as a biomarker in sepsis, but its diagnostic and prognostic value has remained unclear in human studies. Here, we aimed at clarifying the value of MIF as a sepsis biomarker with the meta-analysis of clinical trials. PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched until December 2019. From the included studies, blood MIF levels and indicators of disease severity were extracted in septic and control patient groups. Twenty-one eligible studies were identified, including data from 1876 subjects (of which 1206 had sepsis). In the septic patients, blood MIF levels were significantly higher than in healthy controls with a standardized mean difference (SMD) of 1.47 (95% confidence interval, CI: 0.96–1.97; p < 0.001) and also higher than in patient groups with nonseptic systemic inflammation (SMD = 0.94; CI: 0.51–1.38; p < 0.001). Markedly greater elevation in blood MIF level was found in the more severe forms of sepsis and in nonsurvivors than in less severe forms and in survivors with SMDs of 0.84 (CI: 0.45–1.24) and 0.75 (CI: 0.40–1.11), respectively (p < 0.001 for both). In conclusion, blood MIF level is more elevated in systemic inflammation caused by infection (i.e., sepsis) compared to noninfectious causes. In more severe forms of sepsis, including fatal outcome, MIF levels are higher than in less severe forms. These results suggest that MIF can be a valuable diagnostic and prognostic biomarker in sepsis given that well-designed clinical trials validate our findings.Janos ToldiDavid NemethPeter HegyiZsolt MolnarMargit SolymarNelli FarkasHussain AlizadehZoltan RumbusEszter PakaiAndras GaramiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Janos Toldi David Nemeth Peter Hegyi Zsolt Molnar Margit Solymar Nelli Farkas Hussain Alizadeh Zoltan Rumbus Eszter Pakai Andras Garami Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
description	Abstract The hunt for useful sepsis biomarkers is ongoing. Macrophage migration inhibitory factor (MIF) was implicated as a biomarker in sepsis, but its diagnostic and prognostic value has remained unclear in human studies. Here, we aimed at clarifying the value of MIF as a sepsis biomarker with the meta-analysis of clinical trials. PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched until December 2019. From the included studies, blood MIF levels and indicators of disease severity were extracted in septic and control patient groups. Twenty-one eligible studies were identified, including data from 1876 subjects (of which 1206 had sepsis). In the septic patients, blood MIF levels were significantly higher than in healthy controls with a standardized mean difference (SMD) of 1.47 (95% confidence interval, CI: 0.96–1.97; p < 0.001) and also higher than in patient groups with nonseptic systemic inflammation (SMD = 0.94; CI: 0.51–1.38; p < 0.001). Markedly greater elevation in blood MIF level was found in the more severe forms of sepsis and in nonsurvivors than in less severe forms and in survivors with SMDs of 0.84 (CI: 0.45–1.24) and 0.75 (CI: 0.40–1.11), respectively (p < 0.001 for both). In conclusion, blood MIF level is more elevated in systemic inflammation caused by infection (i.e., sepsis) compared to noninfectious causes. In more severe forms of sepsis, including fatal outcome, MIF levels are higher than in less severe forms. These results suggest that MIF can be a valuable diagnostic and prognostic biomarker in sepsis given that well-designed clinical trials validate our findings.
format	article
author	Janos Toldi David Nemeth Peter Hegyi Zsolt Molnar Margit Solymar Nelli Farkas Hussain Alizadeh Zoltan Rumbus Eszter Pakai Andras Garami
author_facet	Janos Toldi David Nemeth Peter Hegyi Zsolt Molnar Margit Solymar Nelli Farkas Hussain Alizadeh Zoltan Rumbus Eszter Pakai Andras Garami
author_sort	Janos Toldi
title	Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
title_short	Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
title_full	Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
title_fullStr	Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
title_full_unstemmed	Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
title_sort	macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2ced19890280486aa347af94b9db1a03
work_keys_str_mv	AT janostoldi macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT davidnemeth macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT peterhegyi macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT zsoltmolnar macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT margitsolymar macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT nellifarkas macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT hussainalizadeh macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT zoltanrumbus macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT eszterpakai macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials AT andrasgarami macrophagemigrationinhibitoryfactorasadiagnosticandpredictivebiomarkerinsepsismetaanalysisofclinicaltrials
_version_	1718378741492613120

Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials

Ejemplares similares